AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.

AngioDynamics Inc.

The latest update is out from AngioDynamics ( ($ANGO) ). On February 3, 2026, AngioDynamics entered into a Transition and Retirement Agreement with...

AngioDynamics announces CEO transition and leadership retention plan

The latest update is out from AngioDynamics ( ($ANGO) ). On January 14, 2026, President and CEO James Clemmer presented AngioDynamics’ growth strat...

AngioDynamics Highlights Growth Strategy at J.P. Morgan Conference

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Perspective Therapeutics (CATX – Research Report), Warby Parker (...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Perspective Therapeutics (CATX), Warby Parker (WRBY) and AngioDynamics (ANGO)

Angiodynamics, Inc. (($ANGO)) has held its Q2 earnings call. Read on for the main highlights of the call. AngioDynamics Earnings Call Signals Stron...

AngioDynamics Earnings Call Highlights Med Tech Momentum

Today, several major companies are expected to report earnings: AAR (AIR), AngioDynamics (ANGO). Ahead of earnings, TipRanks shows you the expected...

Options Volatility and Implied Earnings Moves Today, January 06, 2026

AngioDynamics ( ($ANGO) ) has provided an update. On January 6, 2026, AngioDynamics reported financial results for its fiscal second quarter ended ...

AngioDynamics posts strong Q2 results, raises 2026 outlook

In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on AngioDynamics, with a price target of $24.00. Takkinen cover...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ANGO	$10.53	+1.01%	386.96K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ANGO	$10.53	+1.0%	386.96K
3
4
5
6

ANGO

ANGO

No Data Available

Get AngioDynamics Inc. Data in Excel

Get AngioDynamics Inc. Data in Excel